Detection and quantification of (R) and (S)-dechloroethylifosfamide metabolites in plasma from children by enantioselective LC/MS/MS

Chirality

Volumn 21, Issue 7, 2009, Pages 674-680

  Aleksa, Katarina ^a,b   Nava Ocampo, Alejandro ^a,b   Koren, Gideon ^a,b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Dechloroethylifosfamide; Enatioselective metabolism; Ifosfamide; Liquid chromatography mass spectrometry; Pediatric

Indexed keywords

2 DECHLOROETHYLIFOSFAMIDE; 3 DECHLOROETHYLIFOSFAMIDE; CHLOROACETALDEHYDE; CYTOCHROME P450 2B6; DRUG METABOLITE; IFOSFAMIDE; UNCLASSIFIED DRUG;

ACCURACY; ADOLESCENT; ADULT; ARTICLE; CANCER PATIENT; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG METABOLISM; DRUG STRUCTURE; ENANTIOMER; ENANTIOSELECTIVITY; HUMAN; INTERMETHOD COMPARISON; LIQUID CHROMATOGRAPHY; PRIORITY JOURNAL; PROCESS OPTIMIZATION; QUANTITATIVE ANALYSIS; RACEMIC MIXTURE; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; STEREOSPECIFICITY; TANDEM MASS SPECTROMETRY;

ACETALDEHYDE; ADOLESCENT; CHILD; CHILD, PRESCHOOL; CHROMATOGRAPHY, LIQUID; CYCLOPHOSPHAMIDE; HUMANS; IFOSFAMIDE; INFANT; MASS SPECTROMETRY; PEDIATRICS; PLASMA CELLS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; STEREOISOMERISM;

EID: 70349544080     PISSN: 08990042     EISSN: 1520636X     Source Type: Journal    
DOI: 10.1002/chir.20662     Document Type: Article

References (23)

1. Granvil CP, Madan A, Sharkawi M, Parkinson A, Wainer IW. Role of CYP2B6 and CYP3A4 in the in vitro N-dechloroethylation of (R)- and (S)-ifosfamide in human liver microsomes. Drug Metab Dispos 1999; 27:533-541.
2. Roy P, Tretyakov O, Wright J, Waxman DJ. Stereoselective metabolism of ifosfamide by human P-450s 3A4 and 2B6. Favorable metabolic properties of R-enantiomer. Drug Metab Dispos 1999;27:1309-1318.
3. Chang TKH, Weber GF, Crespi CL, Waxman DJ. Differential activation of cyclophosphamide and ifosfamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res 1993;53:5629-5637.
4. Weber GF, Waxman DJ. Activation of the anti-cancer drug ifosphamide by rat liver microsomal P450 enzymes. Biochem Pharmacol 1993;45:1685-1694.
5. Aleksa K, Ito S, Koren G. Enantioselective metabolism of ifosfamide by the kidney. Chirality 2006;18:398-405.
6. Aleksa K, Matsell D, Krausz K, Gelboin H, Ito S, Koren G. Cytochrome P450 3A and 2B6 in the developing kidney: implications for ifosfamide nephrotoxicity. Pediatr Nephrol 2005;20:872-885.
7. Aleksa K, Halachmi N, Ito S, Koren G. A tubule cell model for ifosfamide nephrotoxicity. Can J Physiol Pharmacol 2005;83:499-508.
8. Aleksa K, Halachmi N, Ito S, Koren G. Renal ontogeny of ifosfamide nephrotoxicity. J Lab Clin Med 2004;144:285-293.
9. Aleksa K, Ito S, Koren G. Renal-tubule metabolism of ifosfamide to the nephrotoxic chloroacetaldehyde: pharmacokinetic modeling for estimation of intracellular levels. J Lab Clin Med 2004;143:159-162.
10. Springate J, Chan K, Lu H, Davies S, Taub M. Toxicity of ifosfamide and its metabolite chloroacetaldehyde in cultured renal tubule cells. In Vitro Cell Dev Biol Anim 1999;35:314-317.
11. Springate JE. Ifosfamide metabolite chloroacetaldehyde causes renal dysfunction in vivo. J Appl Toxicol 1997;17:75-79.
12. Skinner R, Sharkey IM, Pearson AD, Craft AW. Ifosfamide, mesna, and nephrotoxicity in children. J Clin Oncol 1993;11:173-190.
13. Boddy AV, Yule SM. Metabolism and pharmacokinetics of oxazaphosphorines. Clin Pharmacokinet 2000;38:291-304.
14. Wainer IW, Ducharme J, Granvil CP. The N-dechloroethylation of ifosfamide: using stereochemistry to obtain an accurate picture of a clinically relevant metabolic pathway. Cancer Chemother Pharmacol 1996; 37:332-336.
15. Dechant KL, Brogden RN, Pilkington T, Faulds D. Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer. Drugs 1991;42:428-467.
16. Mulders TM, Keizer, Ouwerkerk J, van der Velde EA, Breimer DD, Mulder GJ. Effect of ifosfamide treatment on glutathione and glutathione conjugation activity in patients with advanced cancers. Clin Cancer Res 1995;1:1525-1536.
17. Goren MP, Wright RK, Pratt CB. Dechloroethylation of ifosfamide and neurotoxicity. Lancet 1989;2:1219-1220.
18. Kerbusch T, de Kraker J, Keizer HJ, van Putten JW, Groen HJ, Jansen RL, Schellens JH, Beijnen JH. Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites. Clin Pharmacokinet 2001;40:41-62.
19. Kerbusch T, Mathot RA, Keizer HJ, Kaijser GP, Schellens JH, Beijnen JH. Influence of dose and infusion duration on pharmacokinetics of ifosfamide and metabolites. Drug Metab Dispos 2001;29: 967-975.
20. Boddy AV, Cole M, Pearson AD, Idle JR. The kinetics of the autoinduction of ifosfamide metabolism during continuous infusion. Cancer Chemother Pharmacol 1995;36:53-60.
21. Wagner T. Ifosfamide clinical pharmacokinetics. Clin Pharmacokinet 1994;26:439-456.
22. Kurowski V, Wagner T. Comparative pharmacokinetics of ifosfamide, 4-hydroxyifosfamide, chloroacetaldehyde, and 2- and 3-dechloroethylifosfamide in patients on fractionated intravenous ifosfamide therapy. Cancer Chemother Pharmacol 1993;33:36-42.
23. Lewis LD, Fitzgerald DL, Harper PG, Rogers HJ. Fractionated ifosfamide therapy produces a time-dependent increase in ifosfamide metabolism. Br J Clin Pharmacol 1990;30:725-732.